Arecoline Fundamentals Explained
MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research To judge several intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Most important trial targets were To guage the security and tolerability of sifalimumab in dermatomyositis or polym